login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
SANOFI-ADR (SNY) Stock News
USA
- NASDAQ:SNY -
US80105N1054
-
ADR
49.76
USD
+2.56 (+5.42%)
Last: 10/1/2025, 9:32:37 PM
50.02
USD
+0.26 (+0.52%)
Pre-Market:
10/2/2025, 8:35:36 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SNY Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: Zacks Investment Research
- Mentions:
GILD
KYMR
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
2 days ago - By: Stocktwits
- Mentions:
NVAX
Novavax Amends Deal With Sanofi, Broadens Partnership
3 days ago - By: Investor's Business Daily
- Mentions:
GSK
AZN
GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley
6 days ago - By: Benzinga
- Mentions:
AMGN
GSK
LLY
Amgen Expands US Manufacturing Network Amid New Tariff Policy
6 days ago - By: Benzinga
Sanofi Expands Insulin Savings Program To Cover All US Patients
7 days ago - By: Stocktwits
- Mentions:
IMRX
Why Immuneering Stock Soared Over 40% After-Hours Today
a month ago - By: Investor's Business Daily
- Mentions:
REGN
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'
6 days ago - By: Sanofi
Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
6 days ago - By: The Motley Fool
- Mentions:
BBAI
MRK
DBD
NVDA
...
Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now
10 days ago - By: Regeneron Pharmaceuticals, Inc.
- Mentions:
REGN
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
a month ago - By: Stocktwits
- Mentions:
DFAX
APIE
Sanofi’s New Experimental Eczema Drug Meets Goals Of Late-stage Trial, But Wall Street Expected More
2 months ago - By: Stocktwits
- Mentions:
NVAX
IWMW
Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification
17 days ago - By: Zacks Investment Research
- Mentions:
REGN
REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?
24 days ago - By: Investor's Business Daily
- Mentions:
DNTH
ARGX
AZN
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
24 days ago - By: Zacks Investment Research
- Mentions:
REGN
LLY
NKTR
NKTR Shares Surge 38.2% in a Week: Here's What You Should Know
a month ago - By: The Motley Fool
- Mentions:
NKTR
Why Nektar Therapeutics Rippled Higher This Week
a month ago - By: Zacks Investment Research
- Mentions:
REGN
ADPT
AKRO
SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study
a month ago - By: Zacks Investment Research
- Mentions:
BMY
NVO
TEVA
TEVA Stock Up More Than 19% in a Month: Buy, Sell or Hold the Stock?
a month ago - By: Zacks Investment Research
- Mentions:
REGN
AZN
MRK
MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline
a month ago - By: Zacks Investment Research
- Mentions:
ADPT
AKRO
ALGS
Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia
a month ago - By: Yahoo Finance
Sanofi (SNY)’s Sarclisa Gets EMA Nod for Multiple Myeloma
a month ago - By: Zacks Investment Research
- Mentions:
AZN
MRK
Will Weak Gardasil Sales Continue to Be a Drag on MRK's Top Line?
2 months ago - By: Yahoo Finance
- Mentions:
UNH
CNC
OSCR
ELV
...
Solar, biotech, and health insurance stocks are rising on Friday: here's why
2 months ago - By: Zacks Investment Research
- Mentions:
REGN
Can Eylea HD and Dupixent Profits Revive Regeneron Stock?
2 months ago - By: Zacks Investment Research
- Mentions:
AMGN
RIGL
SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease
Please enable JavaScript to continue using this application.